Dataset Information

The protective effects of polyphenols on Alzheimer's disease: A systematic review.

ABSTRACT:

Introduction

Foods rich in polyphenols have been positively correlated to a reduced risk of several noncommunicable diseases, including Alzheimer's disease (AD). The aim of this systematic review was to collect and evaluate all the relevant studies on the beneficial effects of polyphenols on AD.

Methods

Studies have been collected through a systematic search on two databases: PubMed and Web of Science. Both randomized controlled trials (RCTs) and observational studies with human subjects were included.

Results

A total of 24 studies were included in this review. Twelve studies found a positive correlation with reduced cognitive decline. Five studies did not find any correlation and seven studies reported mixed results. No conclusive evidence was found for phenolic acids and flavonoids.

Discussion

This systematic review did not find sufficient evidence to confirm that polyphenols have beneficial effects against AD. Further RCTs of human subjects would be necessary to complete the results drawn from this research.

SUBMITTER: Colizzi C

PROVIDER: S-EPMC6551378 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The protective effects of polyphenols on Alzheimer's disease: A systematic review.

Colizzi Chiara C

Alzheimer's & dementia (New York, N. Y.) 20181101

<h4>Introduction</h4>Foods rich in polyphenols have been positively correlated to a reduced risk of several noncommunicable diseases, including Alzheimer's disease (AD). The aim of this systematic review was to collect and evaluate all the relevant studies on the beneficial effects of polyphenols on AD.<h4>Methods</h4>Studies have been collected through a systematic search on two databases: PubMed and Web of Science. Both randomized controlled trials (RCTs) and observational studies with human s ...[more]

PMID: 31194101

Similar Datasets

Project description:BackgroundUsing surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process. A systematic review was undertaken to determine what biomarkers for disease progression in Alzheimer's disease exist and how well they perform.MethodsMEDLINE and Embase (1950-2011) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with probable Alzheimer's disease diagnosed by formal criteria were included. We made no restriction on age, disease duration, or drug treatment. We only included studies with a longitudinal design, in which the putative biomarker and clinical measure were both measured at least twice, as this is the only appropriate study design to use when developing a disease progression biomarker. We included studies which attempted to draw associations between the changes over time in the biomarker used to investigate disease progression and a clinical measure of disease progression.ResultsFifty-nine studies were finally included. The commonest biomarker modality examined was brain MRI (17/59, 29% of included studies). Median follow-up in included studies was only 1.0 (IQR 0.8-1.7) year and most studies only measured the putative biomarker and clinical measure twice. Included studies were generally of poor quality with small numbers of participants (median 31 (IQR 17 to 64)), applied excessively restrictive study entry criteria, had flawed methodologies and conducted overly simplistic statistical analyses without adjusting for confounding factors.ConclusionsWe found insufficient evidence to recommend the use of any biomarker as an outcome measure for disease progression in Alzheimer's disease trials. However, further investigation into the efficacy of using MRI measurements of ventricular volume and whole brain volume appeared to be merited. A provisional 'roadmap' to improve the quality of future disease progression biomarker studies is presented.

Dataset Information

The protective effects of polyphenols on Alzheimer's disease: A systematic review.

Introduction

Methods

Results

Discussion

Publications

The protective effects of polyphenols on Alzheimer's disease: A systematic review.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure